BRAIN Biotech AG has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for BRAIN Biotech AG's Cash Ratio or its related term are showing as below:
During the past 9 years, BRAIN Biotech AG's highest Cash Ratio was 4.66. The lowest was 0.31. And the median was 1.39.
XTER:BNN's Cash Ratio is not ranked *
in the Chemicals industry.
Industry Median: 0.5 * Ranked among companies with meaningful Cash Ratio only.
BRAIN Biotech AG Cash Ratio Historical Data
The historical data trend for BRAIN Biotech AG's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BRAIN Biotech AG's Cash Ratio
For the Specialty Chemicals subindustry, BRAIN Biotech AG's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG's Cash Ratio Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Cash Ratio distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's Cash Ratio falls into.
BRAIN Biotech AG Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
BRAIN Biotech AG's Cash Ratio for the fiscal year that ended in Sep. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRAIN Biotech AG (XTER:BNN) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
BRAIN Biotech AG Cash Ratio Related Terms
Thank you for viewing the detailed overview of BRAIN Biotech AG's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTER:BNN has been successfully added to your 